Facebook
X
LinkedIn
Forward2026 ASTRO Annual Refresher Course onDemand
This course is designed to provide clinicians in practice and trainees with a comprehensive review and update of the clinical practice parameters across most major sub-disciplines of radiation oncology, including skin cancer, sarcomas, pediatrics and lymphomas, and the role of radiotherapy in the multidisciplinary management of cancer patients. The course reviews key evidence that forms the basis for current clinical practice guidelines and trends in new approaches including radiopharmaceutical therapy. In addition, the course covers use of stereotactic, hypofractionated, and adaptive radiation therapy as indicated to improve outcomes for patients. It also provides contouring education for gynecologic, thoracic and genitourinary malignancies.
Target Audience
The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Describe and implement the latest radiation therapy treatment recommendations for clinical scenarios commonly encountered in clinical practice.
- Safely utilize the latest radiation technologies to improve patient care.
- Describe the data and clinical use of protons and heavy ions in the management of patients.
- Appropriately and safely incorporate the treatment of oligometastases into clinical practice.
- Describe the management of benign diseases with radiation.
Day 1
Skin
Moderator: Sue Yom, MD, FASTRO, UCSF
- Speaker: Christopher A. Barker, MD, Memorial Sloan Kettering Cancer Center
Head and Neck
Moderator: Sue Yom, MD, FASTRO, UCSF
- Speaker: Sean M. MCBride, MD, MPH, Memorial Sloan Kettering Cancer Center
Gastrointestinal: Upper and Lower
Moderator: Sue Yom, MD, FASTRO, UCSF
- Speaker: Kimberly Johnung, MD, PhD, Yale School of Medicine
Gynecologic: Endometrial and Cervical
Moderator: Megan E. Daly, MD, University of California Irvine, Chao Family Comprehensive Cancer Center
- Speaker: Lilie Lin, MD, FASTRO, University of Texas, MD Anderson Cancer Center
eContouring for Gynecologic: Vulvar and Vaginal
Moderator: Megan E. Daly, MD, University of California Irvine, Chao Family Comprehensive Cancer Center
- Speaker: Neil K. Taunk, MD, MS, University of Pennsylvania
Day 2
Adaptive Radiotherapy
Moderator: Megan E. Daly, MD, University of California Irvine, Chao Family Comprehensive Cancer Center
- Speaker: Lauren Henke, MD, MS, University Hospitals/Case Western Reserve University
Central Nervous System
Moderator: Megan E. Daly, MD, University of California Irvine, Chao Family Comprehensive Cancer Center
- Speaker: Michelle Kim, MD, University of Michigan
Breast
Moderator: Megan E. Daly, MD, University of California Irvine, Chao Family Comprehensive Cancer Center
- Speaker: Jose G. Bazan, MD, MS, City of Hope Comprehensive Cancer Center
Lung
Moderator: Megan E. Daly, MD, University of California Irvine, Chao Family Comprehensive Cancer Center
- Speaker: Nitin Ohri, MD, MS, Montefiore-Einstein Comprehensive Cancer Center
eContouring for Thoracic
Moderator: Megan E. Daly, MD, University of California Irvine, Chao Family Comprehensive Cancer Center
- Speaker: Katelyn Atkins, MD, PhD, Cedars-Sinai Medical Center
Day 3
Radiopharmaceuticals
Moderator: Sue Yom, MD, FASTRO, UCSF
- Speaker: Ravi Patel, MD, PhD, University of Pittsburgh Hillman Cancer Center
Lymphomas
Moderator: Sue Yom, MD, FASTRO, UCSF
- Speaker: Andrea K. Ng, MD, MPH, FASTRO, Massachusetts General Brigham, Harvard Cancer Center
Genitourinary
Moderator: Megan E. Daly, MD, University of California Irvine, Chao Family Comprehensive Cancer Center
- Speaker: Nicholas G. Zaorsky, MD, MS, University Hospitals/Case Western Reserve University
eContouring for Genitourinary
Moderator: Megan E. Daly, MD, University of California Irvine, Chao Family Comprehensive Cancer Center
- Speaker: Amar U. Kishan, MD, University of California, Los Angeles
Presenter Disclosures
- Katelyn Atkins, MD, PhD, is employed by Cedars-Sinai Medical Center. Dr. Atkins receives grant/research funding (institution) from Varian Medical Systems.
- Christopher A. Barker, MD, is employed by Memorial Sloan Kettering Cancer Center. Dr. Barker receives grant/research funding (institution) from EMD Serono and Elekta. Dr. Barker receives grant/research funding and Advisory Board role honoraria/travel expenses from Regeneron.
- Jose Bazan, MD, MS, is employed by City of Hope and has no relevant financial relationships to disclose.
- Ralph Ermoian, MD, is employed by the University of Washington and has no relevant financial relationships to disclose.
- B. Ashleigh Guadagnolo, MD, FASTRO, MPH, is employed by MD Anderson Cancer Center and has no relevant financial relationships to disclose.
- Lauren Henke, MD, MS, is employed by University Hospitals. Dr. Henke receives grant/research funding, honoraria and compensation/payment from Varian Medical Systems. Dr. Henke receives Advisory Board role compensation/payment from Elekta.
- Kimberly Johung, MD, PhD, is employed by Yale University School of Medicine and has no relevant financial relationships to disclose.
- Michelle Kim, MD, is employed by the University of Michigan and has no relevant financial relationships to disclose.
- Amar Kishan, MD, is employed by UCLA. Dr. Kishan receives Consultant role honoraria from Varian Medical Systems and Boston Scientific. Dr. Kishan receives grant/research funding (institution) from Janssen, Inc., Point BioPharma and ViewRay Systems and grant/research funding (individual) from Lantheus and Novartis. Dr. Kishan has ownership equity in MiraDx.
- Lilie Lin, MD, FASTRO, is employed by the University of Texas MD Anderson Cancer Center. Dr. Lin receives grant/research funding (institution) from AstraZeneca, Pfizer and Varian.
- Sean McBride, MD, MPH, is employed by Memorial Sloan Kettering Cancer Center and has no relevant financial relationships to disclose.
- Andrea Ng, MD, MPH, FASTRO, is employed by Massachusetts General Brigham and has no relevant financial relationships to disclose.
- Nitin Ohri, MD, MS, is employed by Albert Einstein College of Medicine, Montefiore Medical Center. Dr. Ohri receives grant/research funding (institution) from AstraZeneca, Regeneron and Koneksa. Dr. Ohri serves in an uncompensated role as a principal investigator for Shanghai Henlius Biotech and BeOne Medicines.
- Ravi Patel, MD, PhD, is employed by the University of Pittsburgh Hillman Cancer Center. Dr. Patel receives grant/research funding (institution) from Voximetry and Merck. Dr. Patel received Advisory Board role compensation/payment from GE Healthcare [relationship ended November 2025].
- Neil K. Taunk, MD, MSCTS, is employed by the University of Pennsylvania. Dr. Taunk receives honoraria, travel expenses and compensation/payment from Boston Scientific for Advisory Board, Consultant and Education/Meeting Faculty roles. Dr. Taunk receives grant/research funding, honoraria and compensation/payment from Point BioPharma/Eli Lilly for Advisory Board and Consultant roles. Dr. Taunk receives grant/research funding (institution) from Varian Medical Systems. Dr. Taunk receives honoraria from Novartis and honoraria and travel expenses from GE Healthcare for Advisory Board and Consultant roles. Dr. Taunk received honoraria and travel expenses from GenMab Pharmaceuticals for a Speaker Bureau role [relationship ended May 2024].
- Emi Yoshida, MD, is employed by the University of California San Francisco. Dr. Yoshida received honoraria from Merck [relationship ended June 2025].
- Nicholas Zaorsky, MD, MS, is employed by University Hospitals and has no relevant financial relationships to disclose.
Planner/Moderator Disclosures
- Megan Daly, MD, is employed by University of California Davis. Dr. Daly receives grant/research funding (institution) from Genentech and honoraria from AstraZeneca. Dr. Daly received grant/research funding (institution) from Merck [relationship ended December 2025] and honoraria from Dava [relationship ended October 2024]; Novocure [relationship ended November 2024]; and Bristol Myers Squibb [relationship ended November 2024].
- Sue Yom, MD, PhD, FASTRO, is employed by University of California San Francisco. Dr. Yom receives grant/research funding (institution) from Bristol Myers Squibb, EMD Serono and Johnson & Johnson.
Reviewer Disclosure
- Michael Haddock, MD is employed by the Mayo Clinic and has no relevant financial relationships to disclose.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 23.00 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 23.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 23.00 Certificate of AttendanceThis activity was designated for 23.00 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Member: $799
- Member-in-Training: $599
- Student/Graduate Student Member: $349
- Nonmember: $1049
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until April 5, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.